Portal de Periódicos da CAPES

Prescription of fondaparinux in hospitalised patients

2009; Thieme Medical Publishers (Germany); Volume: 101; Issue: 06 Linguagem: Inglês

10.1160/th09-01-0008

2567-689X

Steven Baroletti, Matthew J. Labreche, Matthew Niles, John Fanikos, Samuel Z. Goldhaber,

Acute Myocardial Infarction Research

Fondaparinux is an antithrombotic agent with unique properties that may offer benefit to patients beyond the current approved indications. To explore the off-label use versus approved use of fondaparinux, we initiated a single-center registry of fondaparinux use. During the 25-month study period, 219 patients were prescribed fondaparinux: 157 (71.7%) for prophylaxis and 62 (28.3%) patients for the treatment of thrombosis. When fondaparinux was used for prophylaxis in our registry, 94% of patients had documentation of heparin-induced thrombocytopenia (HIT). Fondaparinux warrants further evaluation in patients with HIT or suspected HIT. In the meantime, its off-label use may exceed its use for FDA-approved indications.